Overview
Pattern Biosciences develops an in-vitro diagnostics platform for rapid bacterial identification and antibiotic susceptibility testing. It combines single-cell analysis with machine learning; an instrument and proprietary test kits process a clinical sample to identify the pathogen and predict the most effective antibiotic within hours. Unlike traditional methods that take days, this approach speeds up actionable results and uses data from single cells plus ML, with revenue from instrument sales plus consumables. Its goal is to improve patient outcomes, reduce healthcare costs, and help preserve antibiotic effectiveness by enabling faster, more accurate treatment decisions.
Work here?Claim your company
Simplify's take
What believers are saying
- Pattern raised $43 million in November 2025 to fund U.S. clinical and 510(k) work.
- By March 19, 2026, the pneumonia trial passed 1,000 samples across 11 sites.
- Pattern hired David Barreca on July 27, 2026, signaling commercial launch preparation.
What critics are saying
- The Pneumonia ID/AST panel still lacks FDA clearance after the 2025 Series D.
- The urine panel remains investigational, so revenue stays zero until clearance and adoption.
- Competing PCR and culture platforms can lock hospitals in before Pattern reaches reimbursement.
What makes Pattern Biosciences unique
- Pattern Bioscience pairs single-cell microbiology with machine learning for direct-from-specimen ID/AST.
- Its platform reports results in hours, not days, unlike culture-based hospital workflows.
- FDA Breakthrough designations for pneumonia and urine panels validate a multi-assay diagnostic platform.
Help us improve and share your feedback! Did you find this helpful?